SLC6A8 and neoplasm: demonstrated that RGX202, an inhibitor of SLC6A8 transporter, exerts anti‐tumor effects in diverse primary and metastatic CRC models, including patient‐derived xenografts.[57] Our rescue experiments confirmed that, even with ongoing VTN treatment, significant reductions in creatine and ATP levels were observed alongside marked inhibition of CRC progression following the targeted suppression of SLC6A8 via siRNA or RGX202.